Highest-materiality recent filing
DarioHealth extends President & CCO Steven Nelson's medical leave indefinitely
Steven Nelson, President and Chief Commercial Officer, on indefinite medical leave as of July 10, 2026.
DarioHealth appoints veteran healthcare exec John R. Palumbo to board to support commercial scaling
John R. Palumbo, age 75, appointed to DarioHealth board effective April 10, 2026.
Company may issue and sell up to $20M of common stock through ATM program with A.G.P./Alliance Global Partners.
DarioHealth amends charter to allow board to alter bylaws; stockholder approval obtained Jan 29
Amended charter filed Feb 2, 2026 authorizes board to alter/repeal bylaws, subject to stockholder power.
DarioHealth shareholders approve all seven proposals at 2026 Annual Meeting
Directors elected: Hila Karah, Dennis Matheis, Dennis M. McGrath, Erez Raphael, Yoav Shaked, Lawrence Leisure, Adam K. Stern.
Credit agreement amended with Callodine Commercial Finance on Nov 5, 2025.
DarioHealth launches strategic review, raises $17.5M via private placement
Board formed Special Committee, engaged Perella Weinberg as advisor to explore sale, merger, or standalone.
DarioHealth accelerates mandatory conversion of Series C & D preferred stock into common stock
Effective Sept 18, 2025: all outstanding Series C, C-2, D, D-1, D-2, D-3 preferred convert to common stock or pre-funded warrants at holder's election.
DarioHealth regains Nasdaq minimum bid price compliance; deficiency closed
Received Nasdaq notice on Sep 12, 2025 confirming compliance with Rule 5550(a)(2).
DarioHealth announces 20-for-1 reverse stock split effective August 28, 2025
Reverse split at 20:1 ratio takes effect at market open on August 28, 2025.
DarioHealth shareholders authorize reverse stock split and increase in authorized shares
All seven director nominees elected with majority support; Hila Karah received the most 'against' votes (1.98M).
DarioHealth appoints Steven M. Nelson as President, retains CCO role
Steven M. Nelson, 52, appointed President effective July 10, 2025, in addition to serving as Chief Commercial Officer.
DarioHealth extends preferred stock lock-up to Feb 2026; amends certificates for warrant dividends
Amended lock-up agreements with Series B/C preferred holders extend restrictive period until February 21, 2026.
DarioHealth extends mandatory conversion period for Series C preferred stock from 15 to 24 months
Mandatory conversion period extended from 15 to 24 months for Series C, C-1, C-2 preferred stock.
DarioHealth enters $32.5M credit agreement with Callodine; warrants issued
Borrowed $32.5M at closing; may draw up to $17.5M more subject to revenue thresholds and lender discretion.
DarioHealth shareholders approve up to 51.7M share issuance and warrant repricing
Vote passed 21.4M for, 0.44M against, 0.08M abstain at special meeting on April 28, 2025.
DarioHealth CFO Zvi Ben-David resigns; Chen Franco-Yehuda appointed CFO effective May 15, 2025
Zvi Ben-David resigns as CFO, Treasurer, Secretary effective May 15, 2025; departure for personal reasons, not due to any disagreement.
DarioHealth receives Nasdaq extension to Sept 15, 2025 to regain $1 bid price
Staff granted additional 180 days until September 15, 2025 to meet Minimum Bid Price Requirement.
DarioHealth dismisses EY as auditor, appoints PwC effective March 12, 2025
EY dismissed as independent auditor; PwC (Kesselman & Kesselman) engaged effective March 12, 2025.
DarioHealth appoints healthcare industry veteran Larry Leisure to board; director Kaplan resigns
Lawrence Leisure appointed to board effective Feb 25, 2025; brings 40 years healthcare experience.
DarioHealth closes $25.6M private placement; targets cash flow positive by end of 2025
Raised $25.6M via convertible preferred stock at conversion prices of $0.73 and $0.83; majority from existing shareholders.
DarioHealth Raises ~$6.8M via Series D Convertible Preferred Private Placement
Sold 4,974 shares of Series D-2 and 1,850 shares of Series D-3 preferred at $1,000 each for ~$6.8M gross.
All seven nominees elected: Hila Karah, Dennis Matheis, Dennis M. McGrath, Erez Raphael, Yoav Shaked, Jon Kaplan, and Adam K. Stern.
DarioHealth raises ~$18.8M via preferred stock; amends Avenue loan to extend maturity
Closed private placement of 7,055 Series D and 11,750 Series D-1 preferred shares at $1,000 each, raising $18.8M.
DarioHealth receives Nasdaq delisting notice for bid price below $1.00
Nasdaq notice on Sept 16, 2024: closing bid price below $1.00 for 30 consecutive business days.
DarioHealth extends Series B-3 mandatory conversion period and increases dividends
Mandatory conversion period extended from 15 to 18 months from original issue date.
DarioHealth amends Series B and B-1 Preferred Stock, extends conversion period, adds dividends
Mandatory conversion period extended from 15 to 18 months from original issue date.
Stockholders approve Twill acquisition share issuance and 3M share increase to equity plan
Proposal 1: Approved share issuance upon exercise of warrants and RSUs from Twill acquisition and warrant re-pricing; 16,262,466 for, 1,191,420 against.
DarioHealth appoints Steven Nelson as CCO; President Richard Anderson departs
Steven Nelson, formerly CEO of Contigo Health (Premier Inc.), named Chief Commercial Officer effective June 5, 2024.
Twill had revenue of $18.2M in 2023, net loss of $30.7M.
DarioHealth reduces stockholder meeting quorum to 33 1/3%
Amended Bylaws adopted April 16, 2024, lowering quorum from prior level to 33-1/3% of outstanding voting stock.
CFO Zvi Ben-David's base salary raised to $350,000 effective April 4, 2024.
DarioHealth closes $22.4M preferred stock offering with Aegis Capital
Closed offering of Series C, C-1, C-2 Preferred Stock on Feb 21, 2024.
DarioHealth posts updated investor presentation; no material new data disclosed
Filed updated investor presentation under Item 7.01 on Feb 22, 2024.
DarioHealth acquires Twill for $10M cash + ~10M pre-funded warrants; raises $22.4M PIPE
Acquisition expected to nearly double pro forma 2023 revenue, to ~$30.5M combined.
DarioHealth annual meeting results: directors elected, say-on-pay approved, frequency set to 3 years
All seven director nominees elected with majority support; Hila Karah received 10,656,884 votes for.
DarioHealth holds Investor Day; exhibit content not fully available for summary
Filing announces Investor Day presentation on October 17, 2023.
Preliminary Q2 2023 revenue $6.0-6.15M, driven by B2B channel growth for 10th consecutive quarter.
Removed provision in May 1, 2023 warrants that adjusted exercise price upon future equity raise below $3.334 per share.
DarioHealth amends 8-K; clarifies warrant & Series A-1 shares; closed $15.4M equity & $30M loan
Raised $15.4M gross from sale of Series B, B-1, B-2, B-3 Preferred Stock at $1,000 per share.
DarioHealth completes $15.4M preferred stock placement and $30M credit facility refinancing
Raised ~$15.4M via convertible preferred stock (Series B, B-1, B-2, B-3) at $1,000/share; conversion prices $3.334-$3.392.
DarioHealth confirms no cash or securities at Silicon Valley Bank
DarioHealth has no cash deposits or securities at Silicon Valley Bank.
DarioHealth appoints Jon Kaplan to board of directors
Jon Kaplan appointed to board effective February 22, 2023; board expanded by one seat.
DarioHealth Reports Preliminary FY2022 Revenue of $27.5M and Begins Loan Repayment
Preliminary full-year 2022 total revenue expected $27.5M, up from $20.5M in 2021.
COO Dror Bacher terminated effective Jan 23, 2023; retained as advisory board member.
DarioHealth settles stockholder class action over director removal bylaw; pays $75K in fees
Settled Chavakula v. DarioHealth Corp. challenging a bylaw allowing board to remove directors with/without cause.
DarioHealth stockholders approve amendment to 2020 Equity Incentive Plan increasing share reserve
Stockholders approved Plan Amendment increasing 2020 Plan share reserve to 3,868,514 shares plus annual evergreen increase of 6% of outstanding fully diluted shares for 2021-2025.
DarioHealth sets 2022 annual meeting for Dec 7, record date Oct 13
Annual meeting scheduled for Dec 7, 2022 at 4:00 p.m. Israel time at Caesarea office.
DarioHealth Q2 revenue $6.2M (+17.5% YoY); net loss $18M; strategic shift to B2B2C
Q2 revenue $6.2M, up 17.5% YoY but down 23.3% sequentially; gross margin 18.4% (pro-forma 36.1%).
DarioHealth secures $50M non-dilutive credit facility with OrbiMed; $25M drawn at close
$50M senior secured term loan from OrbiMed; $25M funded at closing, $25M available before June 30, 2023 subject to revenue thresholds.
On July 10, 2026, the temporary medical leave of absence of Steven Nelson, President and Chief Commercial Officer of DarioHealth Corp., or the Company, was extended for an indefinite period.
On April 18, 2025, the Board of Directors of the Company appointed Chen Franco-Yehuda, age 41, to serve as the Company’s Chief Financial Officer, Treasurer and Secretary, effective as of May 15, 2025.
On April 18, 2025, Mr. Zvi Ben-David resigned as Chief Financial Officer, Treasurer and Secretary of DarioHealth Corp. (the “Company”), effective as of May 15, 2025.
On February 25, 2025, on the recommendation of the Nominating Committee of the Board of Directors, or the Board, of DarioHealth Corp., or the Company, appointed Lawrence Leisure as a member of the Board, effective immediately.
On February 24, 2025, Jon Kaplan voluntarily resigned from his position as a member of the Board.
the Company and Richard Anderson, the Company’s President, mutually agreed for Mr. Anderson to cease serving in his role as President of the Company.
appointed Steven Nelson, age 51, to serve as its Chief Commercial Officer.
On February 15, 2024, the Company appointed Tomer Ben-Kiki, age 53, as Chief Operating Officer of the Company.
expanded the Board by one seat and appointed Jon Kaplan as a member of the Board, effective immediately.
On January 23, 2023, DarioHealth Corp. (the “Company”), through its wholly owned subsidiary Labstyle Innovation Ltd., executed a Termination of Employment and Separation Agreement (the “Agreement”) with Dror Bacher, the Company’s Chief Operating Officer, pursuant to which Mr. Bacher’s position as Chief Operating Officer was terminated with immediate effect.
On May 30, 2022, DarioHealth Corp. (the “Company”) was informed of the death of Prof. Richard Stone, a member of the Company’s Board of Directors (the “Board”).
On November 25, 2021, Mr. Oded Cohen was relieved from his role as General Manager of MSK and he was reassigned to serve as Senior Vice President of Strategy M&A and MSK of DarioHealth Corp.
Max materiality 0.90 · Median 0.53 · Most common event other_material